We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
-15.01%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$461M
AUM Growth
-$222M
Cap. Flow
-$108M
Cap. Flow %
-23.46%
Top 10 Hldgs %
59.88%
Holding
143
New
25
Increased
20
Reduced
27
Closed
54

Top Buys

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$24.9M
2
VTRS icon
Viatris
VTRS
+$13.9M
3
ITRN icon
Ituran Location and Control
ITRN
+$8.4M
4
PFE icon
Pfizer
PFE
+$7.53M
5
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$4.18M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$21.4M
2
BMY icon
Bristol-Myers Squibb
BMY
+$8.36M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$6.09M
4
GOOG icon
Alphabet (Google) Class C
GOOG
+$5.76M
5
INCY icon
Incyte
INCY
+$5.6M

Sector Composition

Rank Sector Weight
1 Healthcare 62.23%
2 Technology 3.77%
3 Utilities 2.89%
4 Communication Services 2.27%
5 Financials 1.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMDZ
51
DELISTED
Immune Design Corp.
IMDZ
$1.99M 0.43%
153,000
– –
ACOR
52
DELISTED
Acorda Therapeutics
ACOR
$1.93M 0.42%
608
-584
-49% -$2.42M
ICL icon
53
ICL Group
ICL
$6.53B
$1.9M 0.41%
437,671
+368,588
+534% +$1.52M
HRTX icon
54
Heron Therapeutics
HRTX
$93.9M
$1.9M 0.41%
100,000
-35,000
-26% -$691K
ABUS icon
55
Arbutus Biopharma
ABUS
$857M
$1.88M 0.41%
454,500
– –
RCKT icon
56
Rocket Pharmaceuticals
RCKT
$340M
$1.85M 0.4%
62,500
-27,500
-31% -$825K
RPTP
57
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
$1.84M 0.4%
400,000
-285,000
-42% -$1.15M
CLVS
58
DELISTED
Clovis Oncology, Inc.
CLVS
$1.81M 0.39%
94,500
– –
BHC icon
59
Bausch Health
BHC
$2.57B
$1.8M 0.39%
68,500
+34,750
+103% +$2.57M
NICE icon
60
Nice
NICE
$5.79B
$1.77M 0.38%
+27,300
New +$1.63M
CLCD
61
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
$1.73M 0.37%
278,337
-7,188
-3% -$44.9K
WAB icon
62
Wabtec
WAB
$49.1B
$1.72M 0.37%
21,704
+8,943
+70% +$620K
PTLA
63
CALL
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$1.63M 0.35%
+80,100
New +$2.54M
IONS icon
64
Ionis Pharmaceuticals
IONS
$8.6B
$1.62M 0.35%
40,000
-41,200
-51% -$1.67M
PTCT icon
65
PTC Therapeutics
PTCT
$5.64B
$1.61M 0.35%
250,000
+183,980
+279% +$3.19M
CRVS icon
66
Corvus Pharmaceuticals
CRVS
$1.12B
$1.61M 0.35%
+110,921
New +$1.59M
CYNA
67
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$1.59M 0.35%
134,037
– –
ORBK
68
DELISTED
Orbotech Ltd
ORBK
$1.56M 0.34%
65,710
-101,909
-61% -$2.21M
PVLA
69
Palvella Therapeutics
PVLA
$1.99B
$1.54M 0.33%
10,125
– –
ALDR
70
DELISTED
Alder Biopharmaceuticals
ALDR
$1.53M 0.33%
62,500
-50,000
-44% -$1.16M
SMMT icon
71
Summit Therapeutics
SMMT
$10.4B
$1.39M 0.3%
198,863
-3,357
-2% -$27.2K
PDSB icon
72
PDS Biotechnology
PDSB
$38.4M
$1.37M 0.3%
7,500
-250
-3% -$44.7K
BLUE
73
DELISTED
bluebird bio
BLUE
$1.27M 0.28%
+2,316
New +$1.42M
SCYX icon
74
SCYNEXIS
SCYX
$48.1M
$1.23M 0.27%
3,808
– –
TRIL
75
DELISTED
Trillium Therapeutics Inc.
TRIL
$1.22M 0.27%
132,300
– –
1 2
3
4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q1 2016 Portfolio in Review

As of Q1 2016, Sphera Funds Management held 143 positions worth $461M, down 32% from $683M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Sphera Funds Management withdrew a net $108M in Q1 2016, closing 54 positions and reducing 27 holdings. Its most notable exit was AbbVie, an estimated $21.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 62% of assets, up from 61% a quarter earlier, followed by Technology and Utilities.

Against the trend, Sphera Funds Management opened a new position in Viatris worth $13.3M.

  • Sphera Funds Management's largest Q1 2016 buy was Viatris: 287,827 shares worth $13.3M.
  • Sphera Funds Management added most to Shire pic in Q1 2016, an estimated $24.9M increase.
  • Sphera Funds Management's biggest Q1 2016 reduction was Celgene Corp, cutting an estimated $4.86M.
  • Sphera Funds Management fully exited AbbVie in Q1 2016, selling an estimated $21.4M.
  • Sphera Funds Management's ten largest holdings make up 60% of its $461M portfolio in Q1 2016.
  • Sphera Funds Management opened 25 new positions and closed 54 in Q1 2016.
  • Sphera Funds Management's portfolio value fell 32% quarter-over-quarter to $461M.

Based on Sphera Funds Management's 13F filing for Q1 2016, filed 16 May 2016.